Anthem Biosciences LimitedANTHEMCorporate

Healthcare Biotechnology Latest results: Jun 2026 6 quarters of data

₹822.15

MCap ₹46,181 Cr · P/E 80.1

Anthem Biosciences Limited — Stock analysis & AI research Anthem Biosciences Limited — Seasonality — best & worst months Anthem Biosciences Limited — Technical indicators & charts Anthem Biosciences Limited — Technical setup — score, trend, support & resistance Anthem Biosciences Limited — Live exchange announcements

📋 High Operating Margin Stocks 📋 High Interest Coverage Stocks 📋 High Promoter Holding Stocks 📋 Mid Cap Stocks List 📈 20-Day Breakdown Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹418 Cr

Sales · Jun 2026

-22.6% YoY

₹151 Cr

Operating Profit · Jun 2026

-21.4% YoY

36.0%

OPM % · Jun 2026

+1.7% YoY

₹120 Cr

Net Profit · Jun 2026

-11.7% YoY

₹2.13

EPS · Jun 2026

-12.3% YoY

📝 Anthem Biosciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Anthem Biosciences Limited reported revenue of ₹418 crore for the quarter ended June 2026 (Q1 FY27), down 22.6% from ₹540 crore in the same quarter last year, and down 31.6% sequentially over the March 2026 quarter.

Net profit fell 11.7% year-on-year to ₹120 crore, from ₹136 crore. Earnings per share (EPS) came in at ₹2.13.

Operating profit stood at ₹151 crore — an operating margin (OPM) of 36.0%, compared with 35.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Anthem Biosciences Limited posted revenue of ₹2,124 crore, with a net profit of ₹592 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,002 crore with a net profit of ₹576 crore.

Valuation snapshot

At the current price of ₹822.15, ANTHEM has a market capitalisation of ₹46,181 crore and a trailing P/E of about 80.1.

Within the Biotechnology industry, it is the 2nd-largest of the 8 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 71.40%, foreign institutional investors (FIIs) 3.79%, domestic institutional investors (DIIs) 12.10%, public shareholders 12.70% of Anthem Biosciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹46,181 Cr

Current Price ?

₹822.1

P/E ?

80.15below ind

Industry P/E ?

106.70

P/B ?

N/A

P/S ?

23.06

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

1.2%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹2,002 Cr

OPM ?

39.6%

Profit after tax (TTM) ?

₹576 Cr

EPS (TTM) ?

₹10.26

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹418 Cr

PAT — latest qtr ?

₹120 Cr

YoY qtr sales growth ?

-22.6%

YoY qtr profit growth ?

-11.7%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

100.0

Current Ratio ?

N/A

Ownership

Promoter holding ?

71.40%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

5.8%

Return 6 months ?

14.0%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	483	540	550	423	611	418	-22.6%	-31.6%
Operating Profit	195	191	218	157	267	151	-21.4%	-43.6%
Other Income	14	23	48	34	52	25	+9.1%	-52.1%
Interest	1	2	3	0	2	1	-44.9%	-55.6%
Depreciation	30	26	33	35	40	30	+13.4%	-25.0%
Profit Before Tax	178	186	230	130	278	145	-22.4%	-48.0%
Net Profit	83	136	173	93	190	120	-11.7%	-36.9%
EPS	1.48	2.43	3.09	1.65	3.38	2.13	-12.3%	-37.0%
OPM %	40.4%	35.4%	39.6%	37.1%	43.7%	36.0%	+1.7%	-17.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY26	TTM	YoY %
Sales	—	₹2,124 Cr	₹2,002 Cr	—
Operating Profit	—	₹834 Cr	₹793 Cr	—
OPM %	—	39.24%	39.59%	—
NPM %	—	27.87%	28.77%	—
Other Income	—	₹157 Cr	₹159 Cr	—
Depreciation	—	₹134 Cr	₹138 Cr	—
Interest	—	₹7 Cr	₹6 Cr	—
EBIT	—	₹699 Cr	₹655 Cr	—
PBT	—	₹824 Cr	₹783 Cr	—
Tax	—	₹144 Cr	₹118 Cr	—
Net Profit	—	₹592 Cr	₹576 Cr	—
EPS	—	₹10.55	₹10.25	—
Material Cost	—	₹548 Cr	₹535 Cr	—
Employee Cost	—	₹210 Cr	₹217 Cr	—
Extraordinary Items	—	₹25 Cr	₹25 Cr	—

👥 Shareholding (latest 1 periods)

Metric	Sep 2026	% Chg
Promoters	71.40%	—
FIIs	3.79%	—
DIIs	12.10%	—
Public	12.70%	—
No. of Shareholders	1,76,209	—

⚖️ Peer comparison

Industry: Biotechnology · 8 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	BIOCON Biocon	₹390.65	63,609	147.4	17,322	417	20.4%	2.4%	10.9%	-74.2%	10.0%	53.4%
2	ANTHEM ANTHEM BIOSCIENCES	₹874.85	49,142	85.4	2,002	576	39.6%	28.8%	—	—	-22.6%	-11.7%
3	ONESOURCE ONESOURCE SPECL	₹1,592.00	18,256	—	1,544	-49	21.9%	-3.2%	-1.6%	-185.0%	37.3%	0.7%
4	CONCORDBIO Concord Biotech	₹1,510.00	15,797	57.6	1,109	273	34.9%	24.6%	-12.1%	-30.4%	26.2%	31.0%
5	514336 CCME Global	₹15.10	150	—	0	-1	-2079.0%	-2135.5%	-98.9%	-120.3%	—	-120.2%
6	511509 Vivo Bio	₹37.69	37	—	55	-3	37.0%	-5.2%	14.3%	-123.4%	14.1%	-86.0%
7	539470 Shree Ganesh	₹1.20	18	—	5	-0	-35.3%	-7.8%	-78.4%	34.2%	3.6%	-273.7%
8	539206 Genomic Valley	₹52.00	9	n/m	0	0	11.7%	6.7%	-68.2%	-94.4%	-57.8%	-26.9%

❓ Frequently asked questions

What was Anthem Biosciences Limited's revenue in Q1 FY27?

What was Anthem Biosciences Limited's net profit in Q1 FY27?